PAMEL

PAMEL occupies a specialized position at the intersection of EEG recording hardware, clinical neurophysiology supplies, biofeedback education, and rehabilitation devices. Its product scope extends beyond a single cap: the portfolio includes the Comby EEG Cap, several EEG electrode types, connection accessories, training, and devices for EMG and pulsed electromagnetic field applications. A stated differentiator is the Comby system’s support for varying electrode types and configurations within a reusable cap, with electrode positions based on the International 10-20 System. The company also describes CE marking, FDA 510(k) approval for Comby caps and electrodes, and ISO 13485-compliant manufacturing, signals relevant to clinical procurement and regulated markets. Its combination of equipment, consumables, and education may serve customers seeking an integrated supplier rather than a hardware-only vendor. Its competitive set likely includes EEG cap and electrode manufacturers, neurofeedback equipment vendors, and broader medical-device suppliers; PAMEL’s stated product breadth and configuration flexibility are the clearest points of distinction.

Its current portfolio suggests a gradual extension from EEG caps and electrodes into adjacent supplies, biofeedback and neurofeedback equipment and education, and devices for physical medicine and rehabilitation. The Comby EEG Cap is the clearest product-level differentiator: it uses International 10-20 electrode placement and supports different electrode configurations. Website information also describes regulatory and quality credentials, including CE marking, FDA 510(k) approval for Comby caps and electrodes, and ISO 13485-compliant manufacturing processes. The company’s employee-size band is 1–10, and there is no stated hiring news or funding history to indicate a recent scaling inflection. Overall, the evidence supports continuity and a focused product portfolio, rather than a documented high-growth trajectory.